LifeStance Health Group (NASDAQ:LFST) Reaches New 12-Month High – Time to Buy?

LifeStance Health Group, Inc. (NASDAQ:LFST)’s stock price reached a new 52-week high during trading on Wednesday. The stock traded as high as $13.77 and last traded at $13.6480, with a volume of 109,401 shares traded. The stock had previously closed at $13.37.

Key Headlines Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: BTIG Research raised its price target to $20 from $18 and maintained a Buy rating. The new target implies 48.7% upside from the cited $13.45 share price. Article: LifeStance Health Group Stock Price Target Raised at BTIG Research
• Positive Sentiment: LifeStance reported third-quarter adjusted earnings of $0.06 per share, beating estimates of $0.04, and revenue of $455.9 million, above the $431.6 million consensus. Revenue increased 25.3% year over year, and the company raised its full-year outlook—supporting investor optimism about growth and profitability. Article: LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Canaccord Genuity Group upped their price objective on LifeStance Health Group from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Weiss Ratings upgraded LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. boosted their target price on LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Wall Street Zen downgraded LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. Finally, Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, LifeStance Health Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.38.

LifeStance Health Group Trading Down 5.4%

The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. The business’s 50 day moving average is $12.59 and its 200 day moving average is $9.46. The stock has a market cap of $5.14 billion, a price-to-earnings ratio of 103.46 and a beta of 1.35.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%. The firm had revenue of $455.86 million for the quarter, compared to analyst estimates of $431.59 million. The company’s revenue for the quarter was up 25.3% compared to the same quarter last year. As a group, equities analysts expect that LifeStance Health Group, Inc. will post 0.16 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Lisa K. Miller sold 47,912 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the sale, the chief operating officer owned 281,289 shares in the company, valued at $3,051,985.65. The trade was a 14.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.62, for a total value of $144,890,858.34. Following the completion of the transaction, the insider directly owned 98,101,407 shares of the company’s stock, valued at $1,041,836,942.34. This trade represents a 12.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 13,777,580 shares of company stock worth $146,433,781. 3.50% of the stock is currently owned by insiders.

Institutional Trading of LifeStance Health Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LFST. KBC Group NV purchased a new stake in LifeStance Health Group in the 1st quarter valued at $29,000. IFP Advisors Inc boosted its stake in LifeStance Health Group by 316.5% during the 2nd quarter. IFP Advisors Inc now owns 3,694 shares of the company’s stock worth $40,000 after purchasing an additional 2,807 shares during the period. EverSource Wealth Advisors LLC grew its position in LifeStance Health Group by 359.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock worth $44,000 after purchasing an additional 5,404 shares during the last quarter. PNC Financial Services Group Inc. grew its position in LifeStance Health Group by 615.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock worth $59,000 after purchasing an additional 7,987 shares during the last quarter. Finally, Assetmark Inc. increased its stake in LifeStance Health Group by 17.0% in the first quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after purchasing an additional 1,367 shares during the period. Institutional investors and hedge funds own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.